Regeneron's pricing deal with federal government may have ‘far-reaching consequences,' analysts sayMarket Watch • 09/15/23
Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/11/23
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at 2023 Wells Fargo Healthcare Conference (Transcript)Seeking Alpha • 09/06/23
OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 StudyBusiness Wire • 09/06/23
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTXBusiness Wire • 09/05/23
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 PreventionGlobeNewsWire • 08/22/23
You're An Amazing Stock Picker If You Bought These 8 Stocks This MonthInvestors Business Daily • 08/22/23
Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis LoomsInvestors Business Daily • 08/21/23
Regeneron Pharmaceuticals shares rise on FDA approval of higher dose of eye disorder drug EYLEAProactive Investors • 08/21/23